Who is sponsoring NCT05610904?

NCT05610904 is sponsored by Changhai Hospital.

What drugs are being tested in NCT05610904?

Interventions in NCT05610904: Prediction model evaluation.

What condition does NCT05610904 study?

NCT05610904 studies Anastomotic Leak Rectum.

Is NCT05610904 still recruiting?

NCT05610904 is currently status unknown. Last updated 9 November 2022.

Last reviewed 2022-11-09 · How we verify

NCT05610904

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of AL Prediction for Rectal Cancer

Status unknown NA Last updated 9 November 2022

What this trial tests

NA trial testing Prediction model evaluation in Anastomotic Leak Rectum in 418 participants. Status unknown.

Timeline

10 December 2022

Primary endpoint
10 October 2024

10 October 2025

Quick facts

Lead sponsor	Changhai Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	418
Start date	10 December 2022
Primary completion	10 October 2024
Estimated completion	10 October 2025
Sites	1 location across China

Drugs / interventions tested

Prediction model evaluation

Conditions studied

Anastomotic Leak Rectum — all drugs for Anastomotic Leak Rectum →

Sponsor

Changhai Hospital

Who can join

Adults 18 to 75, any sex, with Anastomotic Leak Rectum. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Anastomotic leakage is one of the most serious postoperative complications of low rectal cancer, with an incidence of 3%-21%. The occurrence of anastomotic leakage is related to many factors, and the occurrence of anastomotic leakage can be predicted by building a prediction model. Most of the anastomotic leakage prediction models constructed in the past are nomograms, which have limitations in the fitting of model creation. In the previous study, the center took the lead in building a random forest anastomotic leakage prediction model based on machine learning. This study intends to prospectively enroll patients with rectal cancer undergoing anterior abdominal resection and use their clinical data to prospectively verify the efficacy of the anastomotic leakage prediction model, and further improve and promote the prediction model.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Artificial Intelligence Applications in the Treatment of Colorectal Cancer: A Narrative Review.
Yang J, Huang J, Han D, Ma X. · · 2024 · cited 10× · PMID 38187459 · DOI 10.1177/11795549231220320

Verify or expand the search:

Other recruiting trials for Anastomotic Leak Rectum

Currently open trials in the same condition.

NCT05174910 — Investigation of the Benefit of Using an Autologous Platelet-rich Fibrin Matrix (Obsidian ASG®) for Treatment of Anastom · NA · active not recruiting

Other Changhai Hospital trials

Trials by the same sponsor.

NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05610904 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
Last refreshed: 9 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05610904.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing